X4 PharmaceuticalsXFOR
NASDAQBiotech
No cached AI snapshot yet for XFOR.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
45 employees90.92M shares outstandinglisted 2017-11-16
Next earnings ~Feb 2, 2026
About X4 Pharmaceuticals
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
Latest News
Showing market-wide stock news
Euro: 1.150 target nears on Fed risk against US Dollar – ING
WTI falls near $100 as Saudi adds Oman route, US stocks surge
Yield on 10-year Treasury hovers above 5% as investors await Fed decision
Warsh’s Fed expected to hike rates 25bp as dot plot takes center stage
USD/JPY Price Forecast: Retreats from 155.50 with Fed’s policy in focus
Equities: Fed focus and energy shock – Deutsche Bank
Related Stocksin Biotech
Ready to see the live AI view on XFOR?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing XFOR side-by-side with live signals.